For the year ending 2025-12-31, HRMY had $299,501K increase in cash & cash equivalents over the period. $347,889K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net product revenue | 868,453 |
| Cost of product sold | 198,315 |
| Research and development | 144,923 |
| Sales and marketing | 112,136 |
| General and administrative | 100,065 |
| Depreciation and amortization | 25,335 |
| Stock-based compensation | 44,960 |
| Interest expense | 14,649 |
| Interest income | 21,924 |
| Income tax expense | 56,377 |
| Other segment items | 34,930 |
| Net income | 158,687 |
| Depreciation and impairment of long-lived assets | 1,490 |
| Intangible amortization | 23,845 |
| Acquired in-process research & development (ipr&d) expense | 34,250 |
| Stock-based compensation | 44,895 |
| Stock appreciation rights market adjustment | 65 |
| Debt issuance costs amortization | 647 |
| Deferred taxes | -7,301 |
| Amortization of premiums and accretion of discounts on investment securities | 1,521 |
| Other non-cash expenses | 1,325 |
| Trade receivables | 13,754 |
| Inventory | -1,841 |
| Prepaid expenses and other assets | -31,787 |
| Trade payables | 3,949 |
| Other liabilities | 67,994 |
| Net cash provided by operating activities | 348,199 |
| Purchase of investment securities | 86,151 |
| Proceeds from maturities and sales of investment securities | 81,062 |
| Purchase of property and equipment | 310 |
| Payment of milestones | 19,250 |
| Payment of upfront fee related to license agreements | 15,000 |
| Net cash used in investing activities | -39,649 |
| Principal repayment of long-term debt | 16,250 |
| Payments of employee withholding taxes related to stock-based awards | 3,004 |
| Proceeds from exercised options | 10,205 |
| Net cash used in financing activities | -9,049 |
| Net increase in cash, cash equivalents, and restricted cash | 299,501 |
| Cash, cash equivalents, and restricted cash-beginning of period | 453,271 |
| Cash, cash equivalents, and restricted cash-end of period | 752,772 |
Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. (HRMY)